We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
IntelGenx's NDA Resubmission for Rizaport Gets FDA Acceptance
Read MoreHide Full Article
IntelGenx Technologies Corp. (IGXT - Free Report) announced that the FDA has accepted the resubmission of 505(b)(2) new drug application (NDA) for Rizaport oral soluble film 10 mg, which is being developed for the treatment of acute migraine. The FDA has set an action date of Apr 1, 2019.
Shares of IntelGenx rallied 18.6% following this news on Tuesday. However, the stock has plunged 20.3% so far this year compared with the industry’s decline of 9.8%.
Rizaport is a proprietary oral thin-film formulation of rizatriptan, a 5-HT1 receptor agonist and the active drug in Merck’s (MRK - Free Report) Maxalt.
We would like to remind investors that in March 2013, IntelGenx submitted the first NDA for Rizaport along with partner RedHill Biopharma (RDHL - Free Report) . Both companies received a complete response letter (CRL) in exchange from the FDA. The CRL was primarily related to third-party chemistry, manufacturing and controls (CMC) as well as the packaging/labeling of the product. However, back then, the regulatory body did not raise any questions regarding Rizaport’s safety and bio-equivalence data.
Later, in November 2017, both IntelGenx and RedHill announced that they have resubmitted the 505(b)(2) NDA for Rizaport 10 mg to the FDA.
However, last December, RedHill terminated its agreement with IntelGenx for the co-development and commercialization of Rizaport. Redhill’s termination notice was due to a receipt of communication from the FDA, which requested for additional information before the full review of the candidate’s NDA resubmission. The regulatory agency asked for extra data following the NDA refiling earlier in November.
Post this round of events, IntelGenx gained exclusive worldwide rights to develop and commercialize Rizaport.
Zacks Rank & Stock to Consider
IntelGenx currently carries a Zacks Rank #4 (Sell).
BioSpecifics’ earnings estimates have been revised 9.6% upward for 2018 and 16.8% for 2019 over the past 60 days. The stock has jumped 29.7% year to date.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
Image: Bigstock
IntelGenx's NDA Resubmission for Rizaport Gets FDA Acceptance
IntelGenx Technologies Corp. (IGXT - Free Report) announced that the FDA has accepted the resubmission of 505(b)(2) new drug application (NDA) for Rizaport oral soluble film 10 mg, which is being developed for the treatment of acute migraine. The FDA has set an action date of Apr 1, 2019.
Shares of IntelGenx rallied 18.6% following this news on Tuesday. However, the stock has plunged 20.3% so far this year compared with the industry’s decline of 9.8%.
Rizaport is a proprietary oral thin-film formulation of rizatriptan, a 5-HT1 receptor agonist and the active drug in Merck’s (MRK - Free Report) Maxalt.
We would like to remind investors that in March 2013, IntelGenx submitted the first NDA for Rizaport along with partner RedHill Biopharma (RDHL - Free Report) . Both companies received a complete response letter (CRL) in exchange from the FDA. The CRL was primarily related to third-party chemistry, manufacturing and controls (CMC) as well as the packaging/labeling of the product. However, back then, the regulatory body did not raise any questions regarding Rizaport’s safety and bio-equivalence data.
Later, in November 2017, both IntelGenx and RedHill announced that they have resubmitted the 505(b)(2) NDA for Rizaport 10 mg to the FDA.
However, last December, RedHill terminated its agreement with IntelGenx for the co-development and commercialization of Rizaport. Redhill’s termination notice was due to a receipt of communication from the FDA, which requested for additional information before the full review of the candidate’s NDA resubmission. The regulatory agency asked for extra data following the NDA refiling earlier in November.
Post this round of events, IntelGenx gained exclusive worldwide rights to develop and commercialize Rizaport.
Zacks Rank & Stock to Consider
IntelGenx currently carries a Zacks Rank #4 (Sell).
A better-ranked stock in the same sector is BioSpecifics Technologies Corp , sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
BioSpecifics’ earnings estimates have been revised 9.6% upward for 2018 and 16.8% for 2019 over the past 60 days. The stock has jumped 29.7% year to date.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>